PA5-20979

antibody from Invitrogen Antibodies

Targeting: ZEB1 AREB6, BZP, FECD6, NIL-2-A, PPCD3, TCF8, ZEB, Zfhep, Zfhx1a

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-20979

Provider

Invitrogen Antibodies

Product name

ZEB1 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

A suggested positive control is Hela cell lysate.

Concentration

1 mg/mL

References

Submitted references

Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells.

Aedo-Aguilera V, Carrillo-Beltrán D, Calaf GM, Muñoz JP, Guerrero N, Osorio JC, Tapia JC, León O, Contreras HR, Aguayo F
Oncology reports 2019 Nov;42(5):2139-2148

---

miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy.

Nagesh PKB, Chowdhury P, Hatami E, Boya VKN, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM
Cancers 2018 Aug 25;10(9)

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of HeLa cell lysate using a ZEB1 polyclonal antibody (Product # PA5-20979) at 1 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western Blot analysis of ZEB1 in HeLa cell lysate with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 1 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot was performed using Anti-ZEB1 Polyclonal Antibody (Product # PA5-20979) and a 124 kDa band corresponding to ZEB1 was observed across all cell lines and decreased upon Doxorubicin treatment in Hep G2. Whole cell extracts (30 µg lysate) of HeLa (Lane 1), Hep G2 (Lane 2), Hep G2 treated with Doxorubicin (1mM for 24 hr) (Lane 3), MCF-7 (Lane 4) were electrophoresed using NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1ug/ml) and detected by Goat anti-Rabbit IgG (H+L), Superclonal™ Recombinant Secondary Antibody, HRP conjugate (Product # A27036, 1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry staining of HeLa cells using a ZEB1 polyclonal antibody (Product # PA5-20979) at a 20 µg/mL dilution.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of HeLa cells using a ZEB1 polyclonal antibody (Product # PA5-20979) at a 20 µg/mL dilution.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry of ZEB1 in HeLa cells with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 20 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry of ZEB1 in K562 cells with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 2.5 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of ZEB1 in Hela cells with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 20 µg/mL.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemistry of ZEB1 in human liver tissue with ZEB1 Polyclonal Antibody (Product # PA5-20979) at 5 µg/mL.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 6 miR-205-NPs inhibits EMT signaling and sensitizes Dtxl treatment in PrCa cells. ( A ) miR-205-NPs treatment suppresses the migratory ability of C4-2 and PC-3 cells in presence/absence of the drug through Boyden chamber study. Images were captured at 20x magnification. Transwell assay with matrigel was performed to detect invasion activity of PrCa cells transfected with miR-205. Docetaxel treatments at 5 nM concentration. Scale bar: 200 um. ( B ) Protein profiling studies of Control, miR-205 transfected and miR-205-NPs treated PrCa cells for 24 h for EMT signaling. Note: miR-205-L or miR-205-Lipo represents same and indicates to miR-205 transfected with lipofectamine.